Immunic Presents New Phase 2 Data Supporting Vidofludimus Calcium in Progressive MS
NEW YORK, May 28, 2026 Immunic, Inc. has unveiled new analyses from its Phase 2 CALLIPER trial evaluating vidofludimus...
APEX Trial
Advertisement
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Apogee Therapeutics Lands $1.3B Blackstone Deal
SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...
Apogee to Reveal Phase 2 Zumilokibart AD Data
SAN FRANCISCO and BOSTON, May 26, 2026 Apogee Therapeutics announced it will report Part B 16-week clinical data from...
Advertisement
